Company: ANIX
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012701
Chunk: 18

Company: Anixa Biosciences Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 8
Chunk 18
---
within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed
on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different
operating and potential revenue generating characteristics: (i) Cancer Vaccines, (ii) CAR-T Therapeutics, and (iii) Other. The following
represents selected financial information for our segments for the three and six months ended April 30, 2025 and 2024 and as of April
30, 2025 and October 31, 2024 (in thousands):

SCHEDULE OF SEGMENT INFORMATION

    For the Three Months Ended April 30,  
    For the Six Months Ended  April 30, 

    2025  
    2024  
    2025  
    2024 
  
    Net loss: 

    Cancer Vaccines 
    $(1,879) 
    $(1,713) 
    $(3,897) 
    $(3,469)
  
    CAR-T Therapeutics 
     (925) 
     (1,444) 
     (2,101) 
     (2,970)
  
    Other 
     (9) 
     (23) 
     (28) 
     (31)
  
    Total 
    $(2,813) 
    $(3,180) 
    $(6,026) 
    $(6,470)
  
    Net loss 
    $(2,813) 
    $(3,180) 
    $(6,026) 
    $(6,470)

    Total operating costs and expenses 
    $3,003  
    $3,467  
    $6,389  
    $7,076 
  
    Less non-cash stock-based compensation 
     (988) 
     (1,260) 
     (2,043) 
     (2,520)
  
    Operating costs and expenses excluding non-cash stock-based compensation 
    $2,015  
    $2,207  
    $4,346  
    $4,556 

    Operating costs and expenses excluding non-cash stock-based compensation: 

    Cancer Vaccines 
    $1,364  
    $1,160  
    $2,831  
    $2,373 
  
    CAR-T Therapeutics